Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Klemens Budde, MD"'
Autor:
Malte Ziemann, MD, Monika Lindemann, MD, Michael Hallensleben, MD, Wolfgang Altermann, MD, Karina Althaus, MD, Klemens Budde, MD, Gunilla Einecke, MD, Ute Eisenberger, MD, Andrea Ender, PhD, Thorsten Feldkamp, MD, Florian Grahammer, MD, Martina Guthoff, MD, Christopher Holzmann-Littig, MD, Christian Hugo, MD, Teresa Kauke, MD, Stephan Kemmner, MD, Martina Koch, MD, Nils Lachmann, PhD, Matthias Marget, PhD, Christian Morath, MD, Martin Nitschke, MD, Lutz Renders, MD, Sabine Scherer, MD, Julian Stumpf, MD, Vedat Schwenger, MD, Florian Sommer, MD, Bernd Spriewald, MD, Caner Süsal, MD, Daniel Zecher, MD, Falko M. Heinemann, PhD, Murielle Verboom, PhD
Publikováno v:
Transplantation Direct, Vol 10, Iss 9, p e1680 (2024)
Background. Preformed donor-specific HLA antibodies (DSA) are a well-known risk factor in kidney transplantation. There is still considerable debate, however, about the optimal risk stratification among patients with preformed DSA. Additionally, data
Externí odkaz:
https://doaj.org/article/a67c56e5a200414ea670b837dd582929
Autor:
Gregory J. Wilson, MBBS, Kim Van, MBBS, Emma O’Lone, PhD, Allison Tong, PhD, Jonathan C. Craig, PhD, Benedicte Sautenet, PhD, Klemens Budde, MD, Derek Forfang, John Gill, MD, William G. Herrington, MD, Tazeen H. Jafar, MPH, David W. Johnson, PhD, Vera Krane, MD, Adeera Levin, MD, Jolanta Malyszko, PhD, Patrick Rossignol, PhD, Deirdre Sawinski, MD, Nicole Scholes-Robertons, PhD, Giovanni Strippoli, PhD, Angela Wang, PhD, Wolfgang C. Winkelmayer, MD, Carmel M. Hawley, MMedSci, Andrea K. Viecelli, PhD
Publikováno v:
Transplantation Direct, Vol 9, Iss 1, p e1398 (2023)
Background. Cardiovascular disease is a major cause of morbidity and mortality in kidney transplant recipients. Trial evidence to improve cardiovascular outcomes is limited by inconsistent reporting of outcomes, which may also lack patient-relevance.
Externí odkaz:
https://doaj.org/article/dafa5e127e2741c1bbcc88a9fe7226fd
Autor:
Katharina A. Mayer, MD, Konstantin Doberer, MD, Philip F. Halloran, MD, PhD, Klemens Budde, MD, Susanne Haindl, BSc, Jakob Mühlbacher, MD, PhD, Farsad Eskandary, MD, PhD, Thierry Viard, PhD, Silvia Casas, PhD, Bernd Jilma, MD, Georg A. Böhmig, MD
Publikováno v:
Transplantation Direct, Vol 8, Iss 12, p e1406 (2022)
Background. Targeting interleukin-6 (IL-6) was shown to counteract donor-specific antibody production and antibody-mediated rejection (AMR) activity. It is not known whether, or to what extent, IL-6 antagonism modulates biomarkers indicative of tissu
Externí odkaz:
https://doaj.org/article/1b4f38eab9a245a0b1242fec75aaff19
Autor:
Wilfried Gwinner, MD, Annika Karch, PhD, Jan H. Braesen, MD, Abedalrazag A. Khalifa, MD, Jochen Metzger, PhD, Maarten Naesens, MD, Elisabet Van Loon, MD, Dany Anglicheau, MD, Pierre Marquet, PhD, Klemens Budde, MD, Mareen Matz, PhD, Wolfgang Arns, MD, Michael Fischereder, MD, Antje Habicht, MD, Ute Eisenberger, MD, Anja Mühlfeld, MD, Martin Busch, MD, Michael Wiesener, MD, Irina Scheffner, PhD,, Armin Koch, PhD
Publikováno v:
Transplantation Direct, Vol 8, Iss 5, p e1316 (2022)
Background. Timely recognition and treatment of acute kidney graft rejection is important to prevent premature graft failure. A predefined urinary marker set for acute T cell–mediated rejection (TCMR) containing 14 peptides was tested for this purp
Externí odkaz:
https://doaj.org/article/b3e9ed446cae4b729c75c1e914a62033
Autor:
Bilgin Osmanodja, MD, Aylin Akifova, Klemens Budde, MD, Mira Choi, MD, Michael Oellerich, MD, Ekkehard Schütz, MD, Julia Beck, PhD
Publikováno v:
Transplantation Direct, Vol 7, Iss 11, p e778 (2021)
Background. Donor-derived cell-free DNA (dd-cfDNA) is increasingly recognized as a valuable biomarker for acute transplant injury, with possible indications in the detection of cellular or humoral rejection and the guidance of immunosuppressive thera
Externí odkaz:
https://doaj.org/article/59ed5cfb4f81478cbef0ef0ef0823c36
Autor:
Stephan Busque, MD, MSc, FRCSC, Flavio G. Vincenti, MD, Helio Tedesco Silva, MD, Philip J. O’Connell, MD, Atsushi Yoshida, MD, John J. Friedewald, MD, Steven M. Steinberg, MD, Klemens Budde, MD, Emine N. Broeders, MD, Yon Su Kim, MD, Carolyn M. Hahn, BA, Huihua Li, MS, Gary Chan, PharmD
Publikováno v:
Transplantation Direct, Vol 4, Iss 9, p e380 (2018)
Background. Tofacitinib is an oral Janus kinase inhibitor. This open-label, long-term extension (LTE) study (NCT00658359) evaluated long-term tofacitinib treatment in stable kidney transplant recipients (n = 178) posttransplant. Methods. Patients who
Externí odkaz:
https://doaj.org/article/b0a113a41fb849ff85e357bd02831398